Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | AOCs in neuromuscular disorders: Duchenne muscular dystrophy

Arthur Levin, PhD, Avidity Biosciences, La Jolla, CA, discusses antibody-oligonucleotide conjugates (AOCs) and their role in the treatment of neuromuscular disorders. Dr Levin first explains the mechanism of action of AOCs and the challenges associated with delivering these agents to cells. In the case of neuromuscular disorders, the AOCs are built around a monoclonal antibody to the transferrin receptor. A study on a mouse model of Duchenne muscular dystrophy (DMD) showed that using a monoclonal antibody to the transferrin receptor can effectively deliver an oligonucleotide therapeutic. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


Dr Levin is an employee of Avidity Biosciences, a Board member at Stoke Therapeutics, and a SAB member at Atalanta Therapeutics.